Why the study?
Excessive immune and fibrotic responses drive chronic inflammation and fibrosis, highlighting the need to understand fibroblast-immune cell cross talk to develop anti-inflammatory and antifibrotic therapies.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Does not yet change heart failure practice; leaves open targeted trials against fibroblast-immune cross-talk.
The immune and fibrotic responses have evolved to work in tandem to respond to pathogen clearance and promote tissue repair. However, excessive immune and fibrotic responses lead to chronic inflammation and fibrosis, respectively, both of which are key pathological drivers of organ pathophysiology. Fibroblasts and immune cells are central to these responses, and evidence of these two cell types communicating through soluble mediators or adopting functions from each other through direct contact is constantly emerging. Here, we review complex junctions of fibroblast-immune cell cross talk, such as immune cell modulation of fibroblast physiology and fibroblast acquisition of immune cell-like functions, as well as how these systems of communication contribute to organ pathophysiology. We review the concept of antigen presentation by fibroblasts among different organs with different regenerative capacities, and then focus on the inflammation-fibrosis axis in the heart in the complex syndrome of heart failure. We discuss the need to develop anti-inflammatory and antifibrotic therapies, so far unsuccessful to date, that target novel mechanisms that sit at the crossroads of the fibrotic and immune responses.
No takes yet. Share an insight, caveat, or question.
Smolgovsky et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: